Catalent to Supply BeiGene ’s BTK Inhibitor BRUKINSA™ (zanubrutinib)

Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, gene therapies, and consumer health products, today announced...(PRWeb November 21, 2019)Read the full story at https://www.prweb.com/releases/catalent_to_supply_beigenes_btk_inhibitor_brukinsa_zanubrutinib/prweb16740939.htm
Source: PRWeb: Medical Pharmaceuticals - Category: Pharmaceuticals Source Type: news